This paper discusses the administrative aspects of molecular diagnostics in oncology, including US Food and Drug Administration (FDA) oversight, the regulatory approval process, clinical, and ...

When an unidentified respiratory disease began circulating the world in early 2020, molecular biology researchers suddenly found that their work was the world’s top story. Efforts to identify the ...

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key ...

Molecular diagnostics are well-established in clinical medicine. Nonetheless, the markets for these tests remain one of the most attractive growth opportunities in the in vitro diagnostics industry.

Dealmaking was strong among molecular diagnostics (MDx) players during 2021 despite the continuation of the pandemic, with most merger and acquisition (M&A) transactions demonstrating either a pivot ...

Molecular diagnostic (MDx) tests should provide results quickly and reliably. By choosing instruments, reagents, software, services, and support offerings that exist in a single MDx ecosystem, ...

Clinical Utility of Pharmacogenomics and Genetic Testing Remains an Issue Through rapid advances in research and clinical applications, molecular diagnostics has grown from a genomic and proteomic ...

Renal tumor pathology has evolved considerably, expanding from two main types of renal malignant tumors to over 20 distinct types. Diagnostic criteria have advanced from purely morphological features ...

REDMOND, Wash.--(BUSINESS WIRE)--Anavasi Diagnostics, an NIH/RADx funded medical technology company developing novel molecular diagnostic testing for the point-of-care (POC) market, announced the Food ...